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Outcomes, VietnamBackground: Little is known about percutaneous coronary intervention (PCI) practices and outcomes in
low-and middle-income nations, despite its rapid uptake across Asia. For the first time, we report on clin-
ical characteristics and in-hospital outcomes for patients undergoing PCI at a leading cardiac centre in
Vietnam.
Methods: Information on characteristics, treatments, and outcomes of patients undergoing PCI was col-
lected into the first PCI registry through direct interviews using a standardised form, medical record
abstraction, and reading PCI imaging data on secured disks. Subgroup analysis was also conducted to
explore gender differences.
Results: Between September 2017 and May 2018, 1022 patients undergoing PCI were recruited from a
total of 1041 procedures. The mean age was 68.3 years and two thirds were male. While 54.4% of patients
presented with acute coronary syndromes, the rate of ST-elevation myocardial infarction was 14.5%. The
majority of lesions were classified as type B2 and C and the radial artery was the most common access
location for PCI (79.2%). The use of drug-eluting stents was universal and the angiographic success rate
was 99.4%. Cardiac complications following PCI were rare with the exception of major bleeding (2.0%).
Female patients were older with relatively more comorbidities and a higher incidence of major bleeding
than males (p < 0.05).
Conclusions: Findings of this study provide an opportunity to benchmark current PCI practices in
Vietnam, identify possible care gaps and potentially inform the adoption of treatment guidelines as well
as use of prevention strategies.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Percutaneous coronary intervention (PCI) has been demon-
strated to be an effective treatment for coronary heart disease
(CHD) worldwide since its inception in the late 1970s [1,2]. The
procedure has become more widely used in Asia, where CHD was
the leading cause of death (approximately 16.2% of all deaths in
2016) [3,4], with around one million PCIs undertaken in 2016 alone
[5]. Notwithstanding the apparent benefits of PCI, post-procedural
cardiac complications remain a concern, including death, myocar-
dial infarction (MI) and bleeding [6,7].
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occurrence of these adverse cardiac events differed according to
patient characteristics, such as gender, age or comorbidities
[6,8,9]. In Asia, cardiac registries in some high-income countries
have also reported similar findings [10,11], while relevant data
remains limited in lower-and middle-income countries. Addition-
ally, most medical care provided for CHD patients in Asian coun-
tries is based on the European or North American guidelines
developed from large domestic registries [12–14]. It is not clear
whether the non-Asian data reflects the Asian experience, nor
whether the guidelines are well suited to the Asian population.
Thus, data from real-world practice in less developed countries
are very important to establish current benchmarks and determine
appropriate management and preventive strategies for these
populations.
Vietnam is a middle-income nation in South-East Asia, where
PCI has been widely used in modern cardiac based treatments for
CHD, the second leading cause of death [15]. Data pertinent to
PCI is scare on the epidemiology, management and outcomes of
patients undergoing the procedure in Vietnam [16]. The aim of this
paper is to provide novel insights concerning the clinical character-
istics and in-hospital outcomes of patients undergoing PCI in Viet-
nam based on the first PCI registry conducted at a leading cardiac
hospital in Vietnam.2. Methods
2.1. Study setting
Data were derived from a registry, which was established at the
Vietnam National Heart Institute (VNHI), Hanoi, Vietnam during
September 2017-May 2018. Full details of this PCI registry was pre-
viously described [17]. As the leading cardiac centre nationwide,
VNHI provides the highest quality of healthcare services for around
17,000 cardiovascular inpatients and 80,000 out-patients annually.
In 2018, the total number of cardiac interventional procedures
undertaken at VNHI was approximately 12,000 [16]. Initial discus-
sions were held with clinical leaders in cardiology to ensure there
was support for the implementation of the registry by senior clin-
ical and executive staff.
2.2. Data collection
This single-centre, hospital-based registry adapted the data col-
lection forms currently used in the Victorian Cardiac Outcomes and
Melbourne Interventional Group registries, Australia [18,19]. Infor-
mation on demographic, clinical and procedural information, and
outcomes of patients who underwent PCI was recorded on stan-
dardised data abstraction forms with standard definitions for all
fields. The study protocol was approved by the Curtin University
Ethics Committee before the commencement of data collection
(HRE 2017-0378). Patients had the right to opt out of the study
without impacting on their care. Data collection was conducted
by a team of specifically trained local investigators at VNHI.
2.2.1. Patient characteristics
Information on participant demographics, medical history, car-
diovascular risk factors (diabetes, hypertension, dyslipidemia,
cerebrovascular disease), clinical symptoms and presentation
(acute coronary syndrome (ACS), cardiogenic shock, cardiac arrest),
left ventricular ejection fraction, and pre-procedural renal status
was collected via both patient interviews and medical records.
ACS includes unstable angina (UA), non-ST-elevation myocardial
infraction (NSTEMI) or ST-elevation myocardial infraction (STEMI).
STEMI was defined as the presence of at least 0.1-mV ST-segmentelevation or new pathological Q waves in  2 contiguous ECG leads
or new left bundle branch block with elevation of cardiac enzyme
levels above the reference range. NSTEMI was defined if either of
the following was present: elevated cardiac enzyme levels above
the reference range, ST-segment depression, T-wave abnormalities
or ischemic symptoms. UA was named in the presence of pro-
longed chest pain without cardiac enzyme elevation.2.2.2. Procedures and medications
The strategy for the specific coronary intervention (e.g. choice
of stent, medication) was at the discretion of the interventionists.
Injured lesion segments were coded following the classification of
the Syntax Score [20] and guidelines for the lesion type of
American College of Cardiology/ American Heart Association
(ACC/AHA) [21]. A procedure was considered successful if there
was a residual stenosis of less than 10% following coronary stent-
ing and the rate of coronary blood perfusion of Thrombosis in
Myocardial Infarction 2 or 3 flow. Pre and post procedural medi-
cal therapies such as oral antiplatelet, aspirin, anti-thrombin, and
glycoprotein IIb/IIIa inhibitors were evaluated according to the
2016 ACC/AHA guidelines [22]. Medications and procedural data
were obtained by extracting medical records and reading secured
procedural disks.2.2.3. Clinical outcomes
Medical records were extracted to document in-hospital com-
plications including death, new or recurrent MI, cardiogenic
shock, bleeding, post-procedural renal impairment, new require-
ment for dialysis, unplanned target vessel revascularisation
(revascularisation for the previously cured coronary artery) by
PCI or coronary artery bypass grafts (CABG), stent thrombosis,
and stroke. MI was defined as an elevation of cardiac biomarkers
more than 5 the upper limit of normal, and evolutionary
ST-segment elevations or development of new Q-waves in at least
2 contiguous ECG leads. Cardiogenic shock was defined by
hypotension (systolic BP <90 mmHg lasted from 30 min and over,
evidence of end-organ hypo perfusion or elevated filling
pressures).
Bleeding was classified by the Bleeding Academic Research
Consortium [23], and major bleeding was defined by any transfu-
sion or by a drop in haemoglobin  3.0 g/dl. Acute renal impair-
ment was defined as a rise of creatinine  44.2 lmol/L or  25%
up to 5 days after the index PCI, compared to baseline creatinine.
Stroke was defined as the patient’s persistent loss of neurological
function due to an ischaemic or haemorrhagic event [24]. Stent
thrombosis was defined as the occurrence of a thrombus or
angiographic documentation of vessel occlusion within a pre-
existing stent or within 5 mm of the proximal or distal stent
edges [25]. Medical records were reviewed to identify these car-
diac events.2.3. Statistical analysis
Data on demographic, clinical, procedures and outcomes were
presented as numbers (and percentages) for categorical variables,
and means (with standard deviations) for continuous variables.
Descriptive statistics were used to summarise characteristics of
the study participants. Fisher exact or Chi-square tests were under-
taken to compare categorical variables, and Student’s t tests or
analysis of variance (ANOVA) were applied to compare continuous
variables. All p-values were two-tailed with significance defined as
p  0.05. All statistical analyses were performed using the SPSS
statistical package (SPSS Version 20.0 for Windows; SPSS Inc.,
Chicago, IL).
Table 1
Clinical characteristics (n = 1022).
Overall Female Male P value*
Patients 1022 326 (31.9) 696 (68.1) _
Age (years), mean ± SD 68.3 ± 10.3 70.9 ± 9.4 67.0 ± 10.5 <0.0001 y
Kinh people 989 (96.7) 321 (98.5) 667 (95.8) 0.045
From provinces outside Hanoi 796 (77.9) 233 (71.5) 563 (80.9) 0.001
Education
Primary school and lower 83 (8.1) 47 (14.4) 36 (5.2) <0.0001
Secondary school 367 (35.9) 122 (37.4) 245 (35.2)
High school 164 (16.0) 40 (12.3) 124 (17.8)
College and higher 408 (39.9) 117 (35.9) 291 (41.8)
Current/ past occupation
Officer worker 389 (38.1) 120 (36.8) 269 (38.6) <0.0001
Manual worker 163 (15.9) 67 (20.6) 96 (13.8)
Farmer 255 (25.0) 107 (32.8) 148 (21.3)
Tradesperson 64 (6.3) 17 (5.2) 47 (6.8)
Others 151 (14.8) 15 (4.6) 136 (19.5)
Poverty a 44 (4.3) 19 (5.8) 25 (3.6) 0.175
Low income b 762 (74.5) 279 (85.6) 483 (69.4) <0.0001
Body mass index (kg/m2) 0.071
Low (<18.5) 107 (10.5) 38 (11.7) 69 (9.9)
Normal (18.5–22.9) 518 (50.7) 178 (54.6) 340 (48.9)
High (23.0) 397 (38.8) 110 (33.7) 287 (41.2)
ST-elevation myocardial infarction 148 (14.5) 38 (11.7) 110 (15.8) 0.097
Non-ST-elevation myocardial infarction 166 (16.2) 57 (17.5) 109 (15.7) 0.518
Unstable angina 242 (23.7) 83 (25.5) 159 (22.8) 0.402
Non-acute coronary syndrome 466 (45.6) 148 (45.4) 318 (45.7) 0.931
Left ventricular ejection fraction (%), mean ± SD 59.4 (±14.7) 61.7 (±14.6) 58.2 (±14.7) 0.001 y
Moderate to severe renal impairment c 25 (2.4) 5 (1.5) 20 (2.9) 0.283
Cardiogenic shock 11 (1.1) 3 (0.9) 8 (1.1) >0.999
Cardiac arrest 6 (0.6) 2 (0.6) 4 (0.6) >0.999
Data are presented as n (%), otherwise specified.
*Comparing female and male subjects; a Obtained certificates of poor and near poor household; b Individual monthly income < 216 USD with the exchange rate of 23.150
VND; c Creatinine > 200 mmol/L.
Fig. 1. Risk factors of study participants.
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3.1. Patient characteristics
A total of 1022 patients were enrolled into the registry. Of these,
19 patients had a second PCI, meaning a total of 1041 procedures,
treating 1276 lesions.
Demographics and clinical characteristics of participants are
summarized in Table 1. Two-thirds of the study population were
male. The participants’ mean age (±SD) was 68.3 years (10.3) and
females were approximately 4 years older than men (p < 0.0001).
The majority of patients were Kinh (96.7%), the largest ethnic
group in Vietnam, and those living in other provinces outside
Hanoi accounted for nearly 80%. The proportions of participants
with college or higher education, conducting office work and with
a low income were 39.9%, 38.1% and 74.5%, respectively.
In total, 54.4% of the patients presented with ACS, with the
respective prevalence of STEMI, NSTEMI and UA being 14.5%,
16.2% and 23.7% (Table 1). Only 1.1% of the participants experi-
enced cardiogenic shock, and 0.6% had cardiac arrest before PCI.
The prevalence of overweight or obesity (BMI  23.0 kg/m2) was
38.8%. The prevalence of hypertension, previous PCI and hyperlip-
idaemia were 67.2%, 35.1% and 29.9%, respectively (Fig. 1).
Compared with males, females had a lower education level,
monthly income and were more likely to do manual work
(p < 0.0001). Additionally, females also had a higher prevalence
of risk factors such as hypertension, diabetes, and hyperlipidaemia
(p < 0.05) with the exception of current smoking and previous PCI
(p < 0.05) compared to males.3.2. Lesion, procedural characteristics and medications prior to PCI
There were 1276 lesions which required subsequent treatment
within 1041 procedures (Table 2). A total of 1275 lesions was usedfor analysis due to missing information of one lesion. Radial artery
and left anterior descending (LAD) were the most common proce-
dural entry and target vessel (79.2% and 46.7%, respectively). 11.9%
patients were undergone left main PCI. Although 94.2% of the
lesions were type B2 and C according to ACC/AHA classification,
there was a high rate of angiographic success (99.4%). Just above
one-third of the lesions required at least 2 stents and almost 96%
of stents used were over 20 mm in length. Drug eluting stents
(DES) were used in all cases and IVUS was utilized in 3.6% of cases.
Common agents used prior to PCI were antithrombin, clopidogrel
and aspirin, accounting for 36.2%, 80.0% and 97.5%, respectively.
Prior to procedures, patients were given low-molecular-weight-
heparin, while unfractionated heparin was used during PCI.
Compared with females, males were more likely to have disease
in the left main coronary artery, chronic total occlusions, stent
restenosis, and  2 stents per lesion (p < 0.05). They tended to
receive ticagrelor, while their female counterparts were relatively
Table 2






Lesions 1276 406 (31.8) 870 (68.2) _
Percutaneous entry location
Radial 824 (79.2) 263 (79.2) 561 (79.1) >0.999
Femoral 217 (20.8) 69 (20.8) 148 (20.9)
Target vessel
Left main 152 (11.9) 29 (7.1) 123 (14.2) <0.0001
Left anterior descending 596 (46.7) 208 (51.2) 387 (44.5) 0.030
Right coronary 406 (31.8) 118 (29.1) 288 (33.1) 0.164
Circumflex 271 (21.2) 80 (19.7) 191 (22.0) 0.394
PCI with  2 lesions 218 (17.1) 69 (17.0) 149 (17.1) >0.999
Type B2 and C lesions 1202 (94.2) 381 (93.8) 821 (94.5) 0.745
Chronic total occlusion 61 (4.8) 10 (2.5) 51 (5.9) 0.012
Restenotic lesions 64 (5.0) 11 (2.7) 53 (6.1) 0.014
Stents used for each lesion
1 788 (61.8) 271 (66.7) 517 (59.5) 0.015
2 487 (38.2) 135 (33.3) 352 (40.5)
Mean (±SD) 1.5 (±0.71) 1.42 (±0.64) 1.54 (±0.74) 0.002
Stent length > 20 mm 1181 (95.9) 375 (95.2) 806 (96.2) 0.502
Mean stent length (±SD) 34.6 (±8.7) 34.5 (±8.9) 34.7 (±8.7) 0.656
Angiographic success 1267 (99.4) 405 (99.8) 862 (99.2) 0.448
Drug-eluting stent use 1231 (96.5) 394 (97.3) 837 (97.1) 0.998
Balloon only 36 (2.8) 11 (2.7) 25 (2.9)
Guidance of IVUS 46 (3.6) 13 (3.2) 33 (3.8) 0.654
Medications
Fibrinolytic therapy 2 (0.2) 1 (50.0) 1 (50.0) 0.536
Glycorprotein IIb/IIIa 0 (0.0)
Antithrombin therapy 377 (36.2) 111 (34.3) 266 (37.5) 0.227
Ticagrelor 176 (16.9) 35 (10.5) 141 (19.9) <0.0001
Clopidogrel/Ticlopidine 833 (80.0) 284 (85.5) 549 (77.4) 0.003
Aspirin 1015 (97.5) 320 (96.4) 695 (98.0) 0.172
*missing information of one lesion.
Data are presented as n (%), unless specified. IVUS: Intravascular Ultrasound.
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p < 0.05).
3.3. In-hospital outcomes and medications post PCI
Complications following PCI during hospital stay were rarely
observed, with a relatively small proportion of new renal impair-
ment and post-procedural bleeding (3.2% and 2.0%, respectively)
(Table 3). Median length of hospital stay was 2 days and over
92% of patients were treated with aspirin, antiplatelet, angiotensin
receptor blockers and statin post PCI as recommended in the ACC/
AHA guideline [22].
Major bleeding rate was higher in females than males (p < 0.05).
Ticagrelor was commonly used in males, while clopidogrel was fre-
quently prescribed in the latter (p < 0.0001).
4. Discussion
This study was the first to provide novel insights into demo-
graphic and clinical characteristics as well as in-hospital outcomes
of patients undergoing PCI at a leading cardiac interventional cen-
tre in Vietnam. The results indicated gender differences in several
demographic and socioeconomic factors, clinical presentation and
treatment which may be potentially important in the design of
optimal care.
4.1. Demographic and clinical characteristics
The mean age of patients received PCI in our study was eight
year younger than the overall national life expectancy in 2016 of
76.3 [26]. However, this age is higher than average ages of other
PCI populations, including neighbouring countries with similar life
expectancy such as China, Thailand and Malaysia (62.0, 62.7 and57.0 years old, respectively) [27–29] and countries with more eco-
nomical development and higher life expectancy such as Australia,
Japan and South Korea (approximately 63.0–65.0 years old)
[7,18,30]. As patients at VNHI were largely transferred from lower
level hospitals, our study population tended to have more comor-
bidities and older age. Potential barriers to receive timely care such
as medical awareness of patients, economic resource and family
constraints should be further investigated.
The prevalence of non ACS (45.6%), STEMI (14.5%), NSTEMI
(16.2%) and UA (23.7%) were generally comparable to data derived
from a recent study of the national PCI registry in Thailand [31].
However, ACS presentation was more common in other PCI reg-
istries, especially with the proportion of STEMI patients (over
30%) [18,28]. For instance, the China PEACE registry reported that
the prevalence of STEMI, NSTEMI and UA in patients undergoing
PCI was 34.8%, 8.1% and 41.8% respectively [29]. One possible
explanation is that acute patients were more likely to receive med-
ical therapy or PCI in district or provincial hospitals, and only more
severe patients were referred to VNHI.
Consistent with previous studies, including the Asia-Pacific
Evaluation of Cardiovascular Therapies collaborative study [32],
our study participants generally presented with common-
cardiovascular disease risk factors such as hypertension, diabetes,
dyslipidaemia, past PCI, prior stroke and smoking. It is interesting
that the prevalence of most those risk factors in our study was sim-
ilar, despite a much lower proportion of dyslipidaemia (30%). For
instance, some recent studies in China, Thailand, Malaysia and Aus-
tralia showed that approximately two thirds of their patients expe-
rienced hyperlipidaemia [18,28,29,31]. Reasons for such difference
are not clear, but it may be due, in part, to a conceivably healthy
and low-fat diet of our study participants [33]. Indeed, the preva-
lence of prior stroke and prior PCI in our study were among the
highest in comparison with other studies [18,28,29,31]. The rapid
Table 3








New renal impairment 33 (3.2) 11 (3.3) 22 (3.1) >0.999
New dialysis 9 (0.9) 1 (0.3) 8 (1.1) 0.286
Cardiogenic shock 4 (0.4) 1 (0.3) 3 (0.4) >0.999
New/recurrent MI 3 (0.3) 2 (0.6) 1 (0.1) 0.24
Unplanned PCI 2 (0.2) 1 (0.3) 1 (0.1) >0.999
Stent thrombosis 2 (0.2) 2 (0.6) 0 (0.0) 0.102
Major bleeding 21 (2.0) 12 (3.6) 9 (1.3) 0.023
Stroke 5 (0.5) 1 (0.3) 4 (0.6) >0.999
Death 8 (0.8) 4 (1.2) 4 (0.6) 0.47
Hospital length (day), median 2.0 2.0 2.0 0.69
Hospital length > 2 days 33.0 34.3 32.4 0.59
Medications
Aspirin 1033 (99.7) 329 (99.7) 704 (99.7) >0.999
Clopidogrel/Ticlopidine 835 (80.5) 290 (87.8) 545 (77.2) <0.0001
Ticagrelor 201 (19.5) 40 (12.2) 161 (22.9) <0.0001
Beta Blockers 397 (38.5) 138 (41.8) 259 (37.0) 0.125
Angiotensin-receptor blockers 952 (92.2) 308 (93.6) 644 (91.6) 0.317
Statin 1033 (99.7) 330 (100.0) 703 (99.6) 0.556
Other lipid lowering therapy 3 (0.3) 3 (0.9) 0 (0.0) 0.032
Oral anticoagulation therapy 4 (0.4) 2 (0.6) 2 (0.3) 0.956
Data are presented as n (%), unless specified.
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cause of death in Vietnam might explain for this difference [26].
Patterns of gender differences in demographic, socioeconomic
and clinical factors are consistent with prior research [8,34,35].
For example, our study showed females receiving PCI accounted
for nearly one-third of total participants, those females were gen-
erally older and had more comorbidities than males. In our data,
the female to male ratio was 0.47, which contrasts with the general
Vietnamese population group age 64 and above which has a female
to male ratio of 1.6 [36]. This lower incidence of PCI in females
might be explained by the relatively lower priority in families of
females compared to males in Vietnamese culture. This may be
exacerbated by the high cost requirement of the procedure itself
and other hospital treatments in the national centre as VNHI. More
males were transferred from other provinces to VNHI for PCI in
comparison to females (p = 0.001), which may support this theory.
Additionally, presenting females were on average 4 years older
than males (p < 0.0001). The protective impact of oestrogen in
females in delaying the onset of cardiovascular disease is likely
to be part of the explanation [37]. The 4-year age gap also partly
explains more comorbidities seen in females such as hypertension,
diabetes and hyperlipidaemia in our study. The Global Registry of
Acute Coronary Events (GRACE) indicated that, in the group of
patients undergoing cardiac intervention, females had higher rates
of diabetes, hypertension, but were less likely to smoke [9]. Data
from several systematic review with meta-analysis also confirmed
that females with cardiovascular risk factors were more likely to
have incident CHD than males [38,39].
4.2. Lesion, procedural characteristics and medications prior to PCI
The radial artery was the most common entry site of PCI proce-
dures, which is similar to the practice in China [29], but different
from Australia, Japan and Malaysia where the femoral access is
quite popular [28,30,34]. The prevalence of treated lesions classi-
fied as ACC/AHA type B2 and C in our study (94%) is higher than
data in previous studies (60–70%) [18,31]. VNHI is the largest pro-
vider of cardiac intervention nationwide, where patients with PCI
may have advanced coronary lesions subsequent to milder lesions
being treated at other hospitals with potential less experienced
interventionists. Greater number of type B2 and C lesions might
also be attributed to the use of longer stents in our study. Theuse of DES was universal, which contrasts with a more mixed pic-
ture elsewhere [8,34,35]. In our study, not all left main PCIs were
accompanied with IVUS use, partly due to the high cost and the
avaibility of this technique in the centre. Regarding medication
used, our patients were less likely to receive glycoprotein IIb/ IIIa,
but tended to be prescribed with ticagrelor when compared to
their counterparts in other studies [34,40]. Similar to some regio-
nal countries [7,18,28], our data showed the left anterior descend-
ing and the right coronary artery were the most common lesion
locations and the rate of in-stent restenosis was low (5%). The pro-
cedural success rate was as high as other countries in the Asia Paci-
fic (APAC) region, despite some differences in clinical practices
[32].
It is worth mentioning some gender differences observed in the
present study. In general, females receiving PCI had lower procedu-
ral risks relative to males. Results from the GRACE registry indi-
cated that females were more likely to have normal/mild
diseases and less likely to have injured lesion in left main vessel
[9]. Although this is not direct comparison as GRACE contained
patients undergoing catheterization only, our finding is in line with
that result. Similarly, a nationwide study in patients undergoing
PCI in Korea reported that males had more chronic lesions in left
main vessel, and required a higher number of stents than females
[35]. Data from a national cardiovascular registry in America also
revealed that females had a lower risk of angiographic features,
and needed shorter stents [8].
4.3. In-hospital outcomes and medications post PCI
Overall, our data showed lower rates of in-hospital outcomes
among patients undergoing PCI compared with other countries in
the APAC region [32]. For instance, the rate of in-hospital death
(0.8%) was the lowest when compared to the corresponding data
in other studies in China (2.2%), Korea (2.3%) and Australia (2.2%)
[18,29,41]. Our PCI participants were also more likely to have
shorter hospital stay (2 days) than their counterparts in China
(10 days) and Australia (4.2 days) [18,29]. Shorter duration of hos-
pital stay may indicate a low mortality rate before discharge in this
study, and such a potential relationship will be investigated in the
future. Regarding post procedural medication use, our results are
in line with some other reports in Asia. For instance, aspirin was
immediately provided to most patients after PCI procedure and
6 H.T.T. Vu et al. / IJC Heart & Vasculature 31 (2020) 100626remained until post discharge [14]. Despite the wide variation of
dual-anti platelet therapy (DAPT) in the region, aspirin and clopi-
dogrel were also used as the most common DAPT in our study,
so were studies from Korea and China [7,29].
Previous studies have largely reported that, females were at a
higher risk of having complications or worse PCI-specific out-
comes, e.g. death, bleeding or cardiogenic shock than males
[8,34,42]. Likewise, females in our study were more likely to have
major bleeding relative to males. It is possible that females were
older, had a higher prevalence of coronary risk factors, and a smal-
ler body size as well as smaller arteries than males at the time of
PCI procedure [8,35]. It is also worth noting that most current
PCI-based devices and medication therapies have been designed
relatively equally between males and females, without a specific
gender indication [43]. Thus, more focused efforts should be taken
to prevent and reduce bleeding complications in female patients
with PCI.
4.4. Study limitations
There are some limitations to our study. Despite data was col-
lected at the national and biggest cardiac interventional centre in
Vietnam, our findings might not be representative of the whole
nation, particularly in terms of lesion type and uptake of cutting-
edge interventions as VNHI is a single centre only. Furthermore,
some uncertainties and recall errors of patients in self-reporting
the socioeconomic status as well as cardiovascular risk factors
might occur, which can contribute to the differences observed.
Additional dedicated studies should be conducted to provide more
overall views of PCI practices in Vietnam.5. Conclusion
Our study based on the first Vietnamese PCI registry provides an
opportunity to understand current insights of clinical characteris-
tics and in-hospital outcomes of patients undergoing PCI in Viet-
nam. It also indicated gender differences in demographic and
clinical characteristics together with procedural performance and
in-hospital outcomes. The findings may contribute to evaluating
PCI-related practices, identifying the gaps in sex-specific care for
cardiovascular health, and potentially developing appropriate
treatment guidelines.
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